Healthcare / BiotechnologyHKSE
$2.09
-0.09 (-4.13%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-122.5M · quality 65.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
32/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.1B
P/E
69.7x
↑EV/EBITDA
30.7x
↑ROE
-4.3%
↓Gross Margin
74.7%
↑Debt/Equity
-0.05
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-14.1%
FCF CAGR
—
FCF margin
-76.5%
FCF / Net income
-2.58x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $50.0M · net income $14.8M · FCF $-38.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $50.0M | $50.0M | $85.1M | $102.9M | $79.0M |
| Net Income | $14.8M | $14.8M | $-442.6M | $-378.8M | $-483.5M |
| EBITDA | $29.2M | $29.2M | $-406.8M | $-341.4M | $-454.6M |
| EPS | 0.03 | 0.03 | -1.04 | -0.89 | -1.14 |
| Gross Margin | 74.7% | 74.7% | 63.8% | 62.4% | 61.9% |
| Operating Margin | -183.2% | -183.2% | -399.3% | -354.9% | -569.2% |
| Net Margin | 29.6% | 29.6% | -520.1% | -368.3% | -612.2% |
| Balance Sheet | |||||
| Debt/Equity | -0.05 | -0.05 | -0.29 | -3.57 | 0.50 |
| Current Ratio | 0.24 | 0.24 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-38.2M | $-38.2M | $-122.5M | $-319.1M | $-315.8M |
| Returns | |||||
| ROE | -4.3% | -4.3% | 93.3% | 952.1% | -156.7% |
| Valuation | |||||
| P/E | 69.67 | 69.67 | — | — | — |
| EV/EBITDA | 30.74 | 30.74 | — | — | — |
| P/B | — | — | — | — | 3.45 |
| Growth & Yield | |||||
| Revenue Growth | -41.3% | -41.3% | -17.3% | 30.3% | — |
| EPS Growth | 102.9% | 102.9% | -16.9% | 21.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
83.5%
EPS terminal req.
$0.19
Spread vs growth
19.4%
5Y implied EPS CAGR
49.5%
EPS terminal req.
$0.22
Spread vs growth
53.3%
10Y implied EPS CAGR
28.3%
EPS terminal req.
$0.36
Spread vs growth
74.6%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+1448.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.04 → 0.03
Residual
+1448.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.